Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector

International Journal of Cancer

Volumn 119, Issue 5, 2006, Pages 1194-1207

  Popkov, Mikhail ^a   Rader, Christoph ^a,b   Gonzalez, Beatriz ^a   Sinha, Subhash C ^a   Barbas III, Carlos F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Antibodies; Integrins; Melanoma; Tumor models

Indexed keywords

1,3 DIKETONE; ARGINYLGLYCYLASPARTIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 38C2; MONOCLONAL ANTIBODY CP38C2; MONOCLONAL ANTIBODY LM 609; MONOCLONAL ANTIBODY SCS 873; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CATALYSIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COMBINED IMMUNODEFICIENCY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVITY; EFFECTOR CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IMMUNOTHERAPY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FLOW CYTOMETRY; FRUCTOSE-BISPHOSPHATE ALDOLASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTEGRINS; MELANOMA; MICE; NEOPLASM INVASIVENESS; SKIN NEOPLASMS;

EID: 33746344379     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21924     Document Type: Article

References (49)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
2. Kumar CC, Armstrong L. Tumor-induced angiogenesis: a novel target for drug therapy? Emerging Drugs: The Prospects for New Medicines, 1997;2:175-90.
3. Brower V. Tumor angiogenesis-new drugs on the block. Nat Biotechnol 1999;17:963-8.
4. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2003;2:S127-S133.
5. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol 2004;64:207-38.
6. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 1996;12:697-715.
7. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat Rev Drug Discov 2003;2:703-16.
8. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct αv integrins. Science 1995;270:1500-2.
9. Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999;103:1227-30.
10. Kumar CC. Integrin β3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003;4:123-31.
11. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli R, Cheresh DA. Vascular integrin α(v)β3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998;4:2625-34.
12. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 1999;85:375-82.
13. Chattopadhyay N, Chatterjee A. Studies on the expression of α(v)β3 integrin receptors in non-malignant and malignant human cervical tumor tissues. J Exp Clin Cancer Res 2001;20:269-75.
14. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:991-1006, vii. Review.
15. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin distribution in malignant melanoma: association of the β3 subunit with tumor progression. Cancer Res 1990;50:6757-64.
16. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA, Brooks PC. Integrin α(v)β3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999;59:2724-30.
17. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the αvβ3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991;88:1924-32.
18. Cheresh DA. Structure, function and biological properties of integrin αvβ3 on human melanoma cells. Cancer Metastasis Rev 1991;10:3-10.
19. Shattil SJ. Function and regulation of the β3 integrins in hemostasis and vascular biology. Thromb Haemost 1995;74:149-55.
20. Hartman GD, Duggan ME. αvβ(3) Integrin antagonists as inhibitors of bone resorption. Expert Opin Investig Drugs 2000;9:1281-91.
21. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
22. Pasqualini R, Bodorova J, Ye S, Hemler ME. A study of the structure, function and distribution of β5 integrins using novel anti-β5 monoclonal antibodies. J Cell Sci 1993;105 (Part 1):101-11.
23. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915-24.
24. Tucker GC. αv integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003;4:722-31.
25. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA. Targeted antiangiogenic therapy for cancer using vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res 2000;6:3056-61.
26. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS. Pilot study of vitaxin-an angiogenesis inhibitor in patients with advanced leiomyosarcomas. Cancer 2001;92:1347-8.
27. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF. A pilot trial of vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001;16:125-32.
28. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT. CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer 2004;110:326-35.
29. Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov Today 2002;7:1138-43.
30. Miller WH, Alberts DP, Bhatnagar PK, Bondinell WE, Callahan JF, Calvo RR, Cousins RD, Erhard KF, Heerding DA, Keenan RM, Kwon C, Manley PJ, et al. Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic. J Med Chem 2000;43:22-6.
31. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, Varner J, Liu M, Smith EM, Neustadt B, Presta M, Armstrong L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual α(v)β3 and α(v)β5 integrin receptor antagonist. Cancer Res 2001;61:2232-8.
32. Rader C, Sinha SC, Popkov M, Lerner RA, Barbas CF, III. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci USA 2003;100:5396-400.
33. Popkov M, Jendreyko N, McGavern DB, Rader C, Barbas CF, III. Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res 2005;65:972-81.
34. Wagner J, Lerner RA, Barbas CF, III. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes. Science 1995;270:1797-800.
35. Barbas CF, III, Burton DR, Scott JK, Silverman GJ. Phage display: a laboratory manual. NY: Cold Spring Harbor Laboratory Press, 2001.
36. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. Multiple roles for platelet GPIIb/IIIa and αvβ3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002;62:2824-33.
37. Pezzella F, Manzotti M, Di Bacco A, Viale G, Nicholson AG, Price R, Ratcliffe C, Pastorino U, Gatter KC, Altman DG, Harris AL, Pilotti S, Veronesi U. Evidence for a novel non-angiogenic pathway in breast cancer metastasis. Lancet 2000;355:1787-8.
38. Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, Granone P, Nicholson AG, Goldstraw P, Ratcliffe C, Tetlow M, Leigh I, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 2002;86:244-9.
39. Smith JW, Vestal DJ, Irwin SV, Burke TA, Cheresh DA. Purification and functional characterization of integrin αvβ5. An adhesion receptor for vitronectin. J Biol Chem 1990;265:11008-13.
40. Vogel BE, Lee SJ, Hildebrand A, Craig W, Pierschbacher MD, Wong-Staal F, Ruoslahti E. A novel integrin specificity exemplified by binding of the αvβ5 integrin to the basic domain of the HIV Tat protein and vitronectin. J Cell Biol 1993;121:461-8.
41. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
42. Chatterjee S, Brite KH, Matsumura A. Induction of apoptosis of integrin-expressing human prostate cancer cells by cyclic Arg-Gly-Asp peptides. Clin Cancer Res 2001;7:3006-11.
43. Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L, Weinberg KI, Laug WE. αv-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 2002;98:690-7.
44. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
45. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM. αvβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 2003;63:2079-87.
46. Thompson WD, Li WW, Maragoudakis M. The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies. J Pathol 2000;190:330-7.
47. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours. Eur J Cancer 2003;39:917-26.
48. Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M. Adenoviral gene transfer of β3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 1998;153:1435-12.
49. Rader C, Turner JM, Heine A, Shabat D, Sinha SC, Wilson IA, Lerner RA, Barbas CF. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J Mol Biol 2003;332:889-99.